V
Vicente Estrada
Researcher at Hospital Clínico San Carlos
Publications - 162
Citations - 5636
Vicente Estrada is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 28, co-authored 147 publications receiving 4020 citations. Previous affiliations of Vicente Estrada include Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study)
Sergio Serrano-Villar,María Lagarde,Jorge F. Vázquez-Castellanos,Alejandro Vallejo,José I. Bernadino,Nadia Madrid,Mariano Matarranz,Alberto Díaz-Santiago,Carolina Gutiérrez,Alfonso Cabello,Judit Villar-García,José Ramón Blanco,Otilia Bisbal,Talía Sainz,Andrés Moya,Santiago Moreno,María José Gosalbes,Vicente Estrada +17 more
TL;DR: In HIV-infected patients initiating ART at advanced disease, the clear immunological benefits of ART were not enhanced by this nutritional intervention targeting the gut-associated lymphoid tissue and microbiota.
Journal ArticleDOI
Partners of people on ART - a New Evaluation of the Risks (The PARTNER study): design and methods.
Alison Rodger,Tina Bruun,Matthew Weait,Pietro Vernazza,Simon Collins,Vicente Estrada,Jan van Lunzen,Giulio Maria Corbelli,Fiona C Lampe,Andrew N. Phillips,Jens D Lundgren +10 more
TL;DR: This observational study will provide missing information on the absolute risk of HIV transmission for both vaginal and anal sex when the index case is on ART with a VL<50 copies/mL in the absence of condom use.
Journal ArticleDOI
Long-term efficacy and safety of fosamprenavir plus ritonavir versus lopinavir/ritonavir in combination with abacavir/lamivudine over 144 weeks.
Federico Pulido,Vicente Estrada,J.G. Baril,K. Logue,K. Schewe,A. Plettenberg,D. Duiculescu,Linda Yau,Cindy Vavro,Michael L. Lim,C. Pharo +10 more
TL;DR: The findings of the KLEAN study extension support durable viral suppression with both FPV/r and LPV/ r treatment regimens when used in combination with ABC/3TC irrespective of viral load at baseline.
Journal ArticleDOI
Mortality risk assessment in Spain and Italy, insights of the HOPE COVID-19 registry.
Iván J. Núñez-Gil,Cristina Fernández-Pérez,Vicente Estrada,Víctor Manuel Becerra-Muñoz,Ibrahim El-Battrawy,Aitor Uribarri,Inmaculada Fernández-Rozas,Gisela Feltes,María C Viana-Llamas,Daniela Trabattoni,Javier López-Pais,Martino Pepe,Rodolfo Romero,Alex F Castro-Mejía,Enrico Cerrato,Thamar Capel Astrua,Fabrizio D'Ascenzo,Óscar Fabregat-Andrés,José Moreu,Federico Guerra,Jaime Signes-Costa,Francisco Marín,Danilo Buosenso,Alfredo Bardají,Sergio Raposeiras-Roubín,Javier Elola,Ángel Molino,Juan José Gómez-Doblas,Mohammad Abumayyaleh,Álvaro Aparisi,María Molina,Asunción Guerri,Ramón Arroyo-Espliguero,Emilio Assanelli,Massimo Mapelli,José María García-Acuña,Gaetano Brindicci,Edoardo Manzone,María Elizabeth Ortega-Armas,Matteo Bianco,Chinh Pham Trung,María José Núñez,Carmen Castellanos-Lluch,Elisa García-Vázquez,Noemí Cabello-Clotet,Karim Jamhour-Chelh,María Jesús Tellez,Antonio Fernández-Ortiz,Carlos Macaya +48 more
TL;DR: COVID-19 produces important mortality, mostly in patients with comorbidities with respiratory symptoms, and Hydroxychloroquine could be associated with survival benefit, but this data need to be confirmed with further trials.
Posted ContentDOI
Baricitinib plus Standard of Care for Hospitalized Adults with COVID-19
Vincent C. Marconi,Athimalaipet V Ramanan,Stephanie de Bono,Cynthia E. Kartman,Venkatesh Krishnan,Ran Liao,Maria Lucia B. Piruzeli,Jason D Goldman,Jason D Goldman,Jorge Alatorre-Alexander,Rita de Cassia Pellegrini,Vicente Estrada,Mousumi Som,Anabela Cardoso,Sujatro Chakladar,Brenda J. Crowe,Paulo Reis,Xin Zhang,David H. Adams,E. Wesley Ely +19 more
TL;DR: The COVID-BARRIER trial as discussed by the authors evaluated the efficacy and safety of baricitinib, an oral selective Janus kinase 1/2 inhibitor, in addition to standard of care (SOC) in hospitalised adults with COVID19.